Publish in this journal
Journal Information
Vol. 72. Issue 9.
Pages 783-786 (September 2019)
Share
Share
Download PDF
More article options
Vol. 72. Issue 9.
Pages 783-786 (September 2019)
Scientific letter
DOI: 10.1016/j.rec.2018.10.008
Full text access
Circulating MiRNA Dynamics in ST-Segment Elevation Myocardial Infarction-driven Cardiogenic Shock
Dinámica de microARN circulantes en pacientes con infarto agudo de miocardio con elevación del segmento ST con shock cardiogénico
Visits
...
Oriol Iborra-Egeaa, Ferran Ruedab, Päivi Lakkistoc,d, Veli-Pekka Harjolae, Cosme García-Garcíab, Antoni Bayes-Genisa,b,f,g,
Corresponding author
abayesgenis@gmail.com

Corresponding author:
a Grupo ICREC (Insuficiència Cardíaca I Regeneració Cardíaca), Instituto de Investigación en Ciencias de la Salud Germans Trias i Pujol (IGTP), Badalona, Spain
b Servicio de Cardiología y Unidad Coronária, Hospital Universitario Germans Trias i Pujol, Badalona, Spain
c Department of Clinical Chemistry, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
d Minerva Institute for Medical Research, Helsinki, Finland
e Emergency Medicine, University of Helsinki, Department of Emergency Care, Helsinki University Hospital, Helsinki, Finland
f CIBER Cardiovascular, Instituto de Salud Carlos III, Madrid, Spain
g Departmento de Medicina, Universidad Autónoma de Barcelona (UAB), Barcelona, Spain
This item has received
...
Visits
(Daily data update)
Article information
Full Text
Bibliography
Download PDF
Statistics
Figures (1)
Tables (1)
Table 1. Demographic and Clinical Characteristics of the Studied Patients
Full Text
To the Editor,

Cardiogenic shock (CS) occurs in approximately 5% of acute myocardial infarction cases and, despite improvements over the last few decades, it represents the leading cause of in-hospital mortality, remaining as high as 40%.1

MicroRNAs (miRNAs) bind target mRNA and act as posttranscriptional regulators of gene expression. MiRNAs can be detected in the circulation and have been proposed as promising biomarkers due to their robust stability to temperature changes and their resistance to degradation by endogenous RNase activity. More specifically, miR-21 is deregulated under cardiovascular disease conditions such as heart failure. MiR-122 has been reported to play a role in remodeling and fibrosis and in the early identification of ST-segment elevation myocardial infarction (STEMI) patients at higher risk of developing major adverse events after undergoing primary percutaneous coronary intervention (PCI), and has been found to be massively increased in a porcine model of CS.2,3 MiR-320a and miR-423-5p are highly expressed in the fetal heart.4 In addition, miR-320a is elevated in patients with chest pain of ischemic origin.5 MiR-423-5p has been validated in patients with heart failure and its abundance is related to disease severity.6

Therefore, in the present study, we sought to assess the expression dynamics of these miRNAs during the first 24 hours after patient admission to the unit. This prospective observational study included 51 consecutive patients with STEMI complicated with CS (approximately 4% of 1265 STEMI admitted), treated with primary PCI between February 2011 and March 2015. Six were excluded due to mechanical complications, and 2 did not sign the informed consent form and were not included; finally, 43 patients fulfilled the inclusion criteria. All-cause death at 30 days was 44.2% (n=19). In particular, inclusion criteria were systolic blood pressure <90 mmHg (or> 90mmHg with vasopressors for> 30 minutes), signs of poor peripheral perfusion, signs of pulmonary congestion and lack of rapid resolution after primary PCI. Postdischarge deaths were identified by telephone contacts and from electronic patient records.

Baseline demographics and clinical data were recorded during admission (Table 1). Serum samples were obtained at 3 time points (on admission immediately after primary PCI, at 12 hours, and at 24 hours), and stored at −80°C until analysis. Total RNA was extracted from 200μL of serum samples using miRCURY RNA Isolation Kit (Exiqon, Vedbaek, Denmark). A synthetic C elegans miRNA Cel-miR-39 (Qiagen, Hilden, Germany) was spiked in to normalize for extraction efficiency. Reverse transcription was performed with miScript II RT Kit (Qiagen) and quantification was performed using miScript SYBR Green PCR kit (Qiagen) and miRNA-specific miScript primer sets (Qiagen) on Roche LightCycler 480.

Table 1.

Demographic and Clinical Characteristics of the Studied Patients

    No. 
Age, years  67.8±13.3  43 
Male sex  28 (65)  43 
Risk factors
Smoking current/past  13 (30)/11 (25)  43 
Hypertension  27 (63)  43 
Diabetes  19 (44)  43 
Dyslipidemia  23 (53)  43 
Previous MI  3 (7)  43 
Previous PCI  5 (12)  43 
Presentation
Anterior STEMI  28 (65)  43 
SBP, mmHg  96.8±31.6  43 
DBP, mmHg  55.8±17.1  43 
HR, bpm  84.5±29.1  43 
Primary PCI  41 (95)  43 
Time to reperfusion, min  197 [143-291]  41 
Number of diseased vessels
12 (29)  41 
16 (39)  41 
13 (32)  41 
Left main disease  10 (24)  41 
LEVF, %  38.6±13.0  43 
Lactate, mmol/L (on admission)  9.2±6.0 
Haemoglobin, g/dL (on admission)  11.7±2.5  43 
Creatinine, mg/dL (on admission)  1.7±0.7  43 
CK-MB peak, ng/mL  457.4±444.6  43 
cTnI peak, ng/mL  212.2±328.0  43 
Complications     
Out-of-hospital cardiac arrest  15 (35)  43 
Ventricular fibrillation  13 (30)  43 
Complete cardiac block  12 (28)  43 
Management     
Mechanical ventilation  22 (51)  43 
Inotropic drugs  40 (93)  43 
Intra-aortic balloon pump  24 (56)  43 
Other mechanical circulatory support (Impella)  1 (2)  43 
Death at 30 d  19 (44)  43 

CK-MB, creatine kinase-MB; cTnI, cardiac troponin I 99th percentile cutoff value for the upper reference limit: 0.5 ng/mL; DBP, diastolic blood pressure; HR, heart rate; LEVF, left ventricular ejection fraction; MI myocardial infarction; PCI, percutaneous coronary intervention; SBP, systolic blood pressure; STEMI, ST-segment elevation myocardial infarction.

The study was approved by the Clinical Investigation Committee at Germans Trias i Pujol University Hospital and all participants, or their closest authorized relative, provided informed consent according to the declaration of Helsinki.

Analysis of the kinetics of the studied miRNAs revealed a significant increase in miR-320a and miR-423-5p at 12hours compared with baseline (P <.001). However, all studied miRNAs decreased significantly from 12 to 24 hours (P <.001). MiR-21, miR-122, and miR-320a levels decreased significantly to below baseline (P=.006, P=.003, and P=.000, respectively), whereas miR-423-5p levels in the plasma returned to baseline (P=.09; Figure 1).

Figure 1.

MiRNA dynamics in cardiogenic shock. Data are presented as boxplots with the median depicted and outliers as separate dots. The data account for 43 different patients at 0, 12, and 24 hours. **P <.01 and ****P <.001. AU, arbitrary units.

(0.23MB).

In the presence of the multiorgan damage that characterizes CS, the origin of this boost in miR-320a and miR-423-5p at 12 hours is uncertain. Remarkably, the 4 studied miRNAs returned to baseline (or lower) after 24 hours despite the persistence of CS.

Although interesting, these results should be interpreted with caution. The limitations imposed by the small cohort, the small set of miRNAs under consideration, and the focus on STEMI patients should be taken into account, as other circumstances may reflect differently on these miRNA data.

Circulating miRNAs have generated strong expectations as emerging genetic prognosticators in addition to the current peptide bioarmamentarium. Studying the dynamics of these miRNAs, we have been able to dissect a pattern that could indicate an unknown role in CS.

In conclusion, monitoring of miR-21, miR-122, miR-320a, and miR-423-5p in STEMI patients with CS revealed dynamic behavior during the first 24hours after patient admission, with a peak at 12 hours.

Funding

This work was supported by grants from the Ministerio de Educación y Ciencia (SAF2014-59892), Fundació La MARATÓ de TV3 (201502, 201516), CIBER Cardiovascular (CB16/11/00403), CERCA Programme (Generalitat de Catalunya), the Helsinki-Uusimaa Hospital District, the Finnish Foundation for Laboratory Medicine, and the Liv och Hälsa Foundation.

Acknowledgements

We acknowledge Katariina Immonen for technical assistance.

References
[1]
V.P. Harjola, J. Lassus, A. Sionis, et al.
Clinical picture and risk prediction of short-term mortality in cardiogenic shock.
Eur J Heart Fail., 17 (2015), pp. 501-509
[2]
P. Andersson, O. Gidlöf, O.O. Braun, et al.
Levels of liver-specific miR-122 is massively increased in a porcine cardiogenic shock model and attenuated by hypothermia.
[3]
Z.W. Zhang, H. Li, S.S. Chen, Y. Li, Z.Y. Cui, J. Ma.
MicroRNA-122 regulates caspase-8 and promotes the apoptosis of mouse cardiomyocytes.
Braz J Med Biol Res., 2 (2017), pp. e5760
[4]
T. Thum, P. Galuppo, C. Wolf, et al.
MicroRNAs in the Human Heart: A Clue to Fetal Gene Reprogramming in Heart Failure.
Circulation., 116 (2007), pp. 258-267
[5]
Y. Devaux, M. Mueller, P. Haaf, et al.
Diagnostic and prognostic value of circulating microRNAs in patients with acute chest pain.
J Intern Med., 277 (2015), pp. 260-271
[6]
A.J. Tijsen, E.E. Creemers, P.D. Moerland, et al.
MiR 423-5p as a circulating biomarker for heart failure.
Circ Res., 106 (2010), pp. 1035-1039
Copyright © 2018. Sociedad Española de Cardiología
Idiomas
Revista Española de Cardiología (English Edition)

Subscribe to our newsletter

Article options
Tools
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

es en
Política de cookies Cookies policy
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here.